ММВБ 2 961 -0,4%  Nasdaq 8 464 -0,1%  Биткойн 8 736 -3,5%  USD/RUB 63,9483 0,2% 
РТС 1 461 -0,5%  S&P500 3 087 -0,2%  Нефть 62,2 -0,6%  EUR/RUB 70,5330 0,3% 
Dow 27 691 0,0%  FTSE100 7 329 -0,4%  Золото 1 456 -4,9%  EUR/USD 1,1033 0,2% 

Курс акций Pfizer [ISIN: US7170811035]

купить
продать

Pfizer Inc. - Профиль

Pfizer Inc. (Pfizer) – глобальная биофармацевтическая компания. Изобретатель и производителем всемирно известного препарата «Виагра». В 2012 году продажи компании упали на 8% до $57,9 млрд, что было связано с появлением дженериков для ряда ее препаратов, в том числе препарата для снижения уровня холестерина в крови «Липитор». Это одно из наиболее продаваемых лекарств в США и мире. В 2012 году продажи «Липитора» компании Pfizer упали на 60%. Выручка от реализации «Виагры» (6-е место среди наиболее продаваемых препаратов компании) выросла на 4%, до $2,1 млрд.

Акционеры

Название Доля (%)
The Vanguard Group, Inc.7,96
SSgA Funds Management, Inc.5,36
BlackRock Fund Advisors4,82
Capital Research & Management Co. (World Investors)2,67
T. Rowe Price Associates, Inc. (Investment Management)1,93
Geode Capital Management LLC1,51
Northern Trust Investments, Inc.(Investment Management)1,38
Wellington Management Co. LLP1,36
JPMorgan Investment Management, Inc.1,33
State Farm Investment Management Corp.1,08
Norges Bank Investment Management1,04
Massachusetts Financial Services Co.1,02
Dimensional Fund Advisors LP0,87
BlackRock Investment Management (UK) Ltd.0,83
Fisher Asset Management LLC0,80

Адрес

235 East 42nd Street, 10017-5755 New York
а/я:
Телефон: 12127332323
Факс:
Вэб: http://www.pfizer.com

Менеджмент

Rady A. Johnson, CPA
Chief Compliance & Risk Officer, Executive VP
Alexander Roderick MacKenzie, PhD
Chief Development Officer & Executive VP
Frank A. D'Amelio, MBA
Chief Financial Officer & EVP-Business Operations
Dawn Rogers
Chief Human Resources Officer & EVP
Freda C. Lewis-Hall, MD
Chief Patient Officer & Executive Vice President
Mikael Dolsten MD, PhD
Chief Scientific Officer
Lidia L. Fonseca, MBA
Chief Technology Officer & EVP
Scott Gottlieb, MD
Director
Albert Bourla, PhD
Director, Chief Executive & Operating Officer
Laurie J. Olson, MBA
EVP-Strategy, Portfolio & Commercial Operations
Ian C. Read
Executive Chairman
Margi McLoughlin, PhD
Executive Director-World Wide Business Development
Kirsten Lund Jurgensen, PhD
Executive Vice President
Michael Goettler
Executive Vice President
Douglas M. Lankler
Executive Vice President & General Counsel
Sally Susman
Executive Vice President-Corporate Affairs
James Marshall Kilts, MBA
Independent Director
Ronald E. Blaylock, MBA
Independent Director
W. Don Cornwell, MBA
Independent Director
Dan R. Littman MD, PhD
Independent Director
Joseph J. Echevarria
Independent Director
James C. Smith
Independent Director
Helen H. Hobbs MD, PhD
Independent Director
Suzanne Nora Johnson
Independent Director
Ryan Crowe
Investor Relations Officer
Denise Bruns
Late-Phase Development Group Leader
Shantanu Narayen, MBA
Lead Independent Director
Neha Wadhwa
Media Contact
Thomas Biegi
Media Contact
Joan Campion
Media Contact
Angela Hwang, MBA
President-Pfizer Essential Health
John D. Young
President-Pfizer Innovative Health
Andy Schmeltz
President-US Oncology Business Unit
Mark Swindell
President-Vaccines
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP
Mark White
Senior Director & Group Leader-Pain Therapeutics
Tamas Koncz
Senior Medical Director
Loretta V. Cangialosi
Senior Vice President & Controller
John E. Sorrentino
VP & COO-Vaccine Research & Development
John DeYoung
Vice President-Worldwide Business Development
Monika A. Vnuk, MD
Vice President-Worldwide Business Development

Добавить или редактировать инструмент